Basic Information
| LncRNA/CircRNA Name | TUC338 |
| Synonyms | NA |
| Region | GRCh38_12:53464468-53465057 |
| Ensemble | ENSG00000282977 |
| Refseq | NR_109828 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | prostate cancer |
| ICD-0-3 | C61.9 |
| Methods | qRT-PCR etc. |
| Sample | prostate carcinoma tissues as well as non-cancer tissues ,prostate carcinoma cell lines(22Rv1 and DU 145)and Human primary prostate epithelial cells(HPrEC) ,patients and healthy controls blood |
| Expression Pattern | up-regulated |
| Function Description | TUC338 was upregulated in tumor tissues comparing to adjacent healthy tissues of prostate carcinoma patients.Plasma levels of TUC338 were also higher in prostate carcinoma patients than in healthy controls.High plasma level of TUC338 was correlated with poor survival.TUC338 overexpression failed to significantly affect cancer cell proliferation, but promoted cancer cell migration and invasion. MiR-466 overexpression resulted in reduced rates of cancer cell migration and invasion, and also attenuated the effect of TUC338 overexpression.TUC338 may serve as an oncogenic lncRNA in prostate carcinoma by downregulating miR-466. |
| Pubmed ID | 31085276 |
| Year | 2019 |
| Title | LncRNA TUC338 Is Overexpressed in Prostate Carcinoma and Downregulates miR-466 |
External Links
| Links for TUC338 | GenBank HGNC NONCODE |
| Links for prostate cancer | OMIM COSMIC |